AbbVie Short-Term Investments decreased by 33.3% to $28.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 9.7%, from $31.00M to $28.00M. Over 5 years (FY 2020 to FY 2025), Short-Term Investments shows relatively stable performance with a -1.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate strong liquidity and significant 'dry powder' for acquisitions or R&D, while lower levels might suggest cash is being deployed into long-term projects or shareholder returns.
Highly liquid assets and marketable securities that are expected to be converted into cash within one year. For technolo...
Commonly compared against other cash-rich technology peers to assess capital preservation strategies and short-term solvency.
short_term_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.00M | $67.00M | $84.00M | $1.47B | $1.44B | $47.00M | $28.00M | $11.00M | $7.00M | $3.00M | $2.00M | $2.00M | $27.00M | $28.00M | $31.00M | $1.00M | $0.00 | $42.00M | $28.00M |
| QoQ Change | — | +24.1% | +25.4% | >999% | -2.3% | -96.7% | -40.4% | -60.7% | -36.4% | -57.1% | -33.3% | +0.0% | >999% | +3.7% | +10.7% | -96.8% | -100.0% | — | -33.3% |
| YoY Change | — | — | — | — | >999% | -29.9% | -66.7% | -99.3% | -99.5% | -93.6% | -92.9% | -81.8% | +285.7% | +833.3% | >999% | -50.0% | -100.0% | +50.0% | -9.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.